| 32.9229 0.075 (0.23%) | 09-12 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.17 | 1-year : | 45.75 |
| Resists | First : | 33.54 | Second : | 39.17 |
| Pivot price | 33.07 |
|||
| Supports | First : | 32.01 |
Second : | 31.06 |
| MAs | MA(5) : | 32.79 |
MA(20) : | 32.96 |
| MA(100) : | 31.27 |
MA(250) : | 29.59 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 22.9 |
D(3) : | 22.4 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 34.43 | Low : | 25.83 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HART ] has closed above bottom band by 35.7%. Bollinger Bands are 23.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.93 - 33.04 | 33.04 - 33.15 |
| Low: | 32.51 - 32.66 | 32.66 - 32.8 |
| Close: | 32.69 - 32.89 | 32.89 - 33.09 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the index, which was developed by IndexIQ LLC with Candriam Belgium S.A. acting as index consultant to IndexIQ. The index includes securities of large-, mid- and small-capitalization companies that trade in the U.S. and foreign markets, including emerging markets other than China, Egypt, India, Kuwait, Pakistan, Qatar, Saudi Arabia and United Arab Emirates.
Thu, 11 Apr 2024
Nike Bets On Olympics to Boost Performance Sales: Report - Benzinga
Tue, 19 Dec 2023
The 10 Best Healthcare & Biotech ETFs to Buy Now - TheStreet
Tue, 14 Nov 2023
5 Best Performing Healthcare ETFs in 2023 - Insider Monkey
Tue, 07 Feb 2023
Rising Pharma Prices Could Give a Beat to HART ETF - ETF Trends
Wed, 18 May 2022
Why Investment into Women’s Heart Health is Desperately Needed - ETF Trends
Wed, 16 Feb 2022
This ETF is designed to help fight heart disease while making you money. Here’s how - CNBC
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|